<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159051</url>
  </required_header>
  <id_info>
    <org_study_id>EA2/110/15</org_study_id>
    <nct_id>NCT04159051</nct_id>
  </id_info>
  <brief_title>Charité HT-Prostate</brief_title>
  <official_title>Phase II Studie Zur Hyperthermen Salvage-Radiotherapie Bei Prostatakarzinompatienten Mit Biochemischem Rezidiv Nach Prostatektomie</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of regional hyperthermia and salvage radiotherapy is being tested in patients&#xD;
      with biochemically recurrent prostate cancer after radical prostatectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current studies on salvage radiotherapy (sRT) for biochemically recurrent prostate cancer&#xD;
      after radical prostatectomy investigate timing, dose-escalation and androgen deprivation&#xD;
      therapy (ADT) for recurrent prostate cancer. These approaches could either be limited by&#xD;
      radiation-related susceptibility of the anastomosis or by suspected side-effects of ADT. A&#xD;
      phase II protocol was developed to investigate the benefit and tolerability of regional&#xD;
      hyperthermia with moderately dose-escalated sRT. The study hypothesis is that hyperthermic&#xD;
      sRT is a safe and feasible salvage treatment modality. The primary endpoint is safety&#xD;
      measured by frequency of grade 3+ genitourinary (GU) and gastrointestinal (GI) adverse events&#xD;
      (AE) according to Common Toxicity Criteria (CTC) version 4. Feasibility is defined by number&#xD;
      of hyperthermia treatments (n ≥ 7) and feasibility of sRT according to protocol. Target&#xD;
      volume delineation is performed according to the EORTC guidelines. sRT is administered with&#xD;
      single doses of 2 Gy 5×/week to a total dose of 70 Gy to the prostate bed, or alternatively&#xD;
      the total dose only to the area of highest risk and a lower dose to the remaining prostate&#xD;
      bed using a simultaneous boost (SIB) technique. Regional hyperthermia is given 2×/week to a&#xD;
      total of 10 treatments. German centres participate in the phase II trial using intensity&#xD;
      modulated RT (IMRT), volumetric modulated arc technique (VMAT) or tomotherapy. The initiating&#xD;
      centres were participants of the SAKK 09/10 study, where the same patient criteria and target&#xD;
      volume definition (mandatory successful performed dummy run) were applied insuring a high&#xD;
      standardisation of the study procedures.&#xD;
&#xD;
      The introduced phase II study implements modern sRT and regional hyperthermia. If the phase&#xD;
      II study is found to be safe and feasible, a multicenter phase III study might be performed&#xD;
      to test whether the addition of regional hyperthermia to dose-intensified sRT improves&#xD;
      biochemical control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute grade 3+ adverse events</measure>
    <time_frame>up to three months after end of treatment</time_frame>
    <description>Measured according to CTCAE version 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late adverse events</measure>
    <time_frame>up to 36 months after end of treatment</time_frame>
    <description>According to CTCAE version 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) assessment</measure>
    <time_frame>up to 36 months after end of treatment</time_frame>
    <description>Using EORTC questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical progression-free survival</measure>
    <time_frame>up to 36 months after end of treatment</time_frame>
    <description>PSA-rise &gt; 0.4 ng/ml or increasing PSA-level where the initial PSA-level is above 0.4 ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical progression-free survival</measure>
    <time_frame>up to 36 months after end of treatment</time_frame>
    <description>Occurrence of a local recurrence, regional recurrence or distant metastasis. Clinical progression-free survival is defined as the time between trial inclusion and occurrence of clinical progression, start of a new androgen deprivation therapy (see below) or death. Patients without event will be censored at the time of last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time without androgen deprivation therapy (ADT), i.e., time until initiation of ADT</measure>
    <time_frame>up to 36 months after end of treatment</time_frame>
    <description>The time from trial inclusion until start of a new androgen deprivation therapy. Patients without new ADT will be censored at the time of last follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>Combined regional hyperthermia and salvage radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Regional Hyperthermia</intervention_name>
    <description>Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks</description>
    <arm_group_label>Combined regional hyperthermia and salvage radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Lymph node negative adenocarcinoma of the prostate treated with radical prostatectomy&#xD;
             at least 12 weeks before randomization. Tumour stage pT2a-3b, R0-1, pN0 or cN0&#xD;
             according to the UICC TNM 2009; Gleason score available.&#xD;
&#xD;
          2. PSA progression after prostatectomy defined as two consecutive rises with the final&#xD;
             PSA &gt; 0.1 ng/ml or three consecutive rises. The first value must be measured at least&#xD;
             4 weeks after radical prostatectomy.&#xD;
&#xD;
          3. PSA at randomization ≤ 2 ng/ml.&#xD;
&#xD;
          4. No evidence of macroscopic local recurrence or metastatic disease on pre-sRT-MRI&#xD;
             (magnetic resonance imaging; with i.v. contrast) or pre-sRT-CT (multislice computed&#xD;
             tomography with i.v. and oral contrast) of the abdomen and pelvis assessed within 16&#xD;
             weeks prior to randomization.&#xD;
&#xD;
          5. WHO performance status 0-1 at randomization.&#xD;
&#xD;
          6. Age at randomization between 18 and 80 years.&#xD;
&#xD;
          7. Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Persistent PSA value 4-20 weeks after radical prostatectomy &gt; 0.4 ng/ml.&#xD;
&#xD;
          2. Palpable mass in the prostatic fossa, unless histology proves no evidence of&#xD;
             recurrence.&#xD;
&#xD;
          3. Pelvic lymph node enlargement &gt;1 cm in short axis diameter of the abdomen and pelvis&#xD;
             (cN1), unless the enlarged lymph node is sampled and negative.&#xD;
&#xD;
          4. Presence or history of bone metastases. Bone scan is mandatory in cases of clinical&#xD;
             suspicion (e.g., bone pain).&#xD;
&#xD;
          5. Other malignancies within five years before planned sRT; non-melanoma skin cancers are&#xD;
             allowed.&#xD;
&#xD;
          6. ADT or bilateral orchiectomy.&#xD;
&#xD;
          7. Previous pelvic radiotherapy.&#xD;
&#xD;
          8. Hip prosthesis.&#xD;
&#xD;
          9. Metal clusters/markers and patients with a pacemaker.&#xD;
&#xD;
         10. Severe or active co-morbidities impairing the feasibility of hyperthermia or dose&#xD;
             intensified sRT including (but not exclusively limited to):&#xD;
&#xD;
               -  chronic inflammatory bowel disease&#xD;
&#xD;
               -  acute bacterial or fungal infection requiring intravenous antibiotics at the time&#xD;
                  of randomization&#xD;
&#xD;
               -  unstable angina pectoris and/or congestive heart failure requiring&#xD;
                  hospitalization within the last 6 months&#xD;
&#xD;
               -  transmural myocardial infarction within the last 6 months&#xD;
&#xD;
               -  chronic obstructive pulmonary disease exacerbation or other respiratory disorders&#xD;
                  requiring hospitalization or precluding planned treatment within the study at the&#xD;
                  time of randomization&#xD;
&#xD;
               -  psychiatric disorder precluding understanding of information on trial-related&#xD;
                  topics, giving informed consent or filling out QoL questionnaires&#xD;
&#xD;
         11. Concurrent treatment with other experimental drugs or other anti-cancer therapy;&#xD;
             treatment in a clinical trial within 30 days prior to trial entry.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pirus Ghadjar, Prof. Dr.</last_name>
    <email>pirus.ghadjar@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden Württemberg</state>
        <zip>72016</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt-Christian Müller, MD</last_name>
      <email>Arndt-Christian.Mueller@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Arndt-Christian Müller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91012</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Ott, Prof. Dr.</last_name>
      <email>oliver.ott@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Ott, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pirus Ghadjar, Prof. Dr.</last_name>
      <email>pirus.ghadjar@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Marcus Beck, MD</last_name>
      <email>marcus.beck@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Marcus Beck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Zschaeck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Wust, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Müller AC, Zips D, Heinrich V, Lamprecht U, Voigt O, Burock S, Budach V, Wust P, Ghadjar P. Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial. Radiat Oncol. 2015 Jul 8;10:138. doi: 10.1186/s13014-015-0442-4.</citation>
    <PMID>26152590</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Pirus Ghadjar</investigator_full_name>
    <investigator_title>Head of Hyperthermia Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

